

Functional characterization and therapeutic targeting of gene regulatory elements

Nadav Ahituv
UCSF

Disclosures

Equity holder and scientific advisor for Encoded Therapeutics

Equity holder and member of scientific advisory board for
Regel Therapeutics

Equity holder and member of scientific advisory board for
Neomer Diagnostics




LT


2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70
3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 * 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69



Promoters




Enhancers




Enhancers

Silencers



Enhancers

Insulators




Enhancers

Haploinsufficiency: When one functional copy of a gene is not enough


2 normal
copies



Gene levels




1 normal
& 1 mutant copy




- Over 660 genes lead to human disease due to haploinsufficiency

Current treatments for haploinsufficient diseases


'Standard' Drugs



Gene Therapy



CRISPR gene editing




Limitations

- Time
- Cost
- Primarily to treat symptoms

- Dosage
- Tissue-specificity
- Gene length

- Low HDR frequency
- Custom tailoring



Gilbert LA et al. *Cell*. 2013

Perez-Pinera.P et al. *Nature Methods* 2013

CRISPRa as a therapeutic for haploinsufficiency?

CRISPRa



2 normal
copies



1 normal
& 1 mutant copy




Gene levels




***SIM1*, an important obesity gene**

- Transcription factor that is:
 - Required for hypothalamic development
 - Part of the Leptin pathway and controls food intake




- *SIM1* mutations are the second most prevalent coding mutations found in severely obese individuals.

***SIM1* haploinsufficiency leads to severe obesity**




Sim1 haploinsufficiency leads to severe obesity




Can we rescue *Sim1* haploinsufficiency with CRISPRa?


Hypothalamus enhancer

(Kim M. HMG 2013)







CRISPRa for either *Sim1* promoter or enhancer rescues the obesity phenotype




Females




Males



Females



Males






UNITED STATES
800.521.2109 • 650.349.1636
FAX 650.349.3729

CANADA
800.665.5355 • 604.980.2481
FAX 604.987.3299


EUROPE
(+49) 62 21 / 90 50
FAX (+49) 62 21 / 90

Cis-regulatory elements determine dCas9-VP64 tissue activation




Can we develop it as a therapeutic?

AAV




4.7kb packaging capacity




Martini SV Braz J Med Biol Res 2011

Many genes cannot get packaged in AAV







Generated AAV for dCas9-VP64 and also for either sgRNA (targetting *Sim1* promoter or enhancer)




AAV-DJ serotype (chimera of type 2, 8 and 9)

AAV CRISPRa hypothalamus stereotactic injections reduce food intake



Many neurodevelopmental genes are too long to fit into an AAV




Perry
Spratt











Serena
Tamura

***SCN2A* is the top associated gene with ASD**



Scn2a CRISPRa rescues synaptic deficit in mature mice







Coline Arnould
Andrew Blair
Rachael Bradley
Candace Chan
Chengyu Deng
Ryder Easterlin
Sarah Fong
Ilias Georgakopoulos-Soares
Yarden Golan-Maor
Wei Gordon
Yelena Guttman
Lana Harshman
Dianne Laboy Cintron
Weiyu Li
Navneet Matharu
Elizabeth Murray
Hai Nguyen
Mai Nobuhara
Nick Page
Rory Sheng
Jasmine Sims
Serena Tamura
Aki Ushiki
Ofer Yizhar-Barnea
Jingjing Zhao
Xujia Zhou

UCSF

Kevin Bender
Tom Nowakowski
Katie Pollard
Alex Pollen
Jennifer Rosenbluth
Stephan Sanders
Christian Vaisse

Harvard

Martin Hemberg

UW

Vikram Agarwal
Florence Chardon
Jason Klein
Jean-Benoit Lalanne
Beth Martin
Troy McDiarmid
Samuel Regalado
Jay Shendure
Berlin Institute of Health
Martin Kircher
Max Schubach

Postdoc positions available

Funding: NHGRI, NCI, NIMH, NICHD, NHLBI, NIDDK, SFARI,
UCSF, BioMarin, Weill Neurohub, Cri Du Chat foundation